Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jdermsci.2025.02.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Topical sirolimus therapy for cutaneous vascular anomalies: A randomized phase II clinical trial.
J Dermatol
March 2025
Department of Dermatology, Wakayama Medical University, Wakayama, Japan.
The efficacy, safety, and optimal concentration of topical sirolimus gel for treatment of cutaneous lesions of vascular anomalies requires evaluation. This study was a multicenter, double-blind, placebo-controlled, parallel-group, phase II randomized clinical trial. We enrolled patients with venous malformation (n = 27), lymphatic malformation (n = 14), tufted angioma (n = 8), or kaposiform hemangioendothelioma (n = 1).
View Article and Find Full Text PDFTopical Sirolimus Treatment of Recurrent Lymphangioma Circumscriptum.
Int J Dermatol
February 2025
Interdisciplinary Unit of Pediatric Dermatology, Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium.
Topical sirolimus suppresses skin fibrosis in a bleomycin-induced mouse model of systemic sclerosis.
J Dermatol Sci
February 2025
Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan. Electronic address:
Off-label use of commercially available topical sirolimus for keratosis pilaris rubra faciei.
JAAD Case Rep
March 2025
Division of Dermatology, Department of Pediatrics, SSM Health Cardinal Glennon Children's Hospital, St. Louis, Missouri.
Effectiveness and safety of liposomal rapamycin for the treatment of facial angiofibromas in tuberous sclerosis.
Farm Hosp
February 2025
Servicio de Dermatología, Hospital Clínico Universitario, Valencia, España.
Objective: Topical rapamycin is the pharmacological treatment of choice for facial angiofibromas in rare tuberous sclerosis disease. A new, more advanced, and complex formula was developed in our pharmacy service: rapamycin 0.4% liposomal formulation, with better organoleptic characteristics and a more favorable release profile of the active ingredient.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!